- Trials with a EudraCT protocol (147)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
147 result(s) found for: Aflibercept.
Displaying page 6 of 8.
EudraCT Number: 2013-004081-33 | Sponsor Protocol Number: FFCD1302 | Start Date*: 2014-01-30 | |||||||||||
Sponsor Name:Fédération Francophone de Cancérologie Digestive (FFCD) | |||||||||||||
Full Title: EFFICACY AND SAFETY of aflibercept ASSOCIATED WITH A FOLFIRI CHEMOTHERAPY IN 1ST LINE TREATMENT OF PATIENTS SUFFERING FROM METASTATIC COLORECTAL CANCER Phase II - single arm - multicenter | |||||||||||||
Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005549-35 | Sponsor Protocol Number: E10030-02 | Start Date*: 2014-04-10 | |||||||||||
Sponsor Name:Barcelona Macula Foundation Research for Vision | |||||||||||||
Full Title: An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of FovistaTM (Anti-PDGF... | |||||||||||||
Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000225-27 | Sponsor Protocol Number: KS301P107 | Start Date*: 2021-10-26 | ||||||||||||||||||||||||||
Sponsor Name:Kodiak Sciences Inc. | ||||||||||||||||||||||||||||
Full Title: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal A... | ||||||||||||||||||||||||||||
Medical condition: Neovascular (Wet) Age-related Macular Degeneration (wAMD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) HU (Completed) LV (Completed) SK (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002738-36 | Sponsor Protocol Number: AKST4290-205 | Start Date*: 2019-10-30 | |||||||||||
Sponsor Name:Alkahest, Inc. | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 with Loading Doses of Aflibercept in Patients with Newly Diagnosed Neovascular Age-Related Macular ... | |||||||||||||
Medical condition: Newly Diagnosed Neovascular Age-Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002219-33 | Sponsor Protocol Number: DISTINCTIVE | Start Date*: 2018-01-24 | |||||||||||
Sponsor Name:FONDAZIONE GISCAD (GRUPPO ITALIANO PER LO STUDIO DEI CARCINOMI DELL'APPARATO DIGERENTE) | |||||||||||||
Full Title: seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status | |||||||||||||
Medical condition: The study will a be a biologically enriched, prospectively stratified phase II trial in RAS wild type metastatic colorectal cancer patients progressing after first-line treatment with oxaliplatin, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002261-15 | Sponsor Protocol Number: ADVM-022-11 | Start Date*: 2023-03-23 | |||||||||||
Sponsor Name:Adverum Biotechnologies, Inc. | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-relat... | |||||||||||||
Medical condition: Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003018-42 | Sponsor Protocol Number: OPH1004 | Start Date*: 2014-10-10 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination wi... | ||||||||||||||||||
Medical condition: Subfoveal neovascular age-related macular degeneration | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Prematurely Ended) ES (Prematurely Ended) FI (Completed) NO (Completed) DE (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) IT (Completed) AT (Prematurely Ended) HU (Completed) HR (Prematurely Ended) CZ (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002773-38 | Sponsor Protocol Number: AIO-KRK-0214 | Start Date*: 2016-12-20 | |||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||
Full Title: mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial | |||||||||||||||||||||||
Medical condition: Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000456-26 | Sponsor Protocol Number: Tumorspheres_Colrec | Start Date*: 2017-07-10 | |||||||||||
Sponsor Name:Vejle Hospital | |||||||||||||
Full Title: Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumorspheres from patients with metastatic colorectal cancer | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000519-42 | Sponsor Protocol Number: OPH1008 | Start Date*: 2015-10-26 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therap... | ||||||||||||||||||
Medical condition: Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003651-42 | Sponsor Protocol Number: AVT06-GL-C01 | Start Date*: 2022-04-14 | |||||||||||
Sponsor Name:Alvotech Swiss AG | |||||||||||||
Full Title: A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age related Macular D... | |||||||||||||
Medical condition: Neovascular (wet) Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) SK (Completed) CZ (Completed) HU (Completed) BG (Completed) LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001875-35 | Sponsor Protocol Number: PRODIGE71-BEVAMAINT | Start Date*: 2019-11-06 | |||||||||||
Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon | |||||||||||||
Full Title: BEVAMAINT - A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer | |||||||||||||
Medical condition: Unresectable metastatic colorectal cancer with measurable hepatic lesions (according to RECIST V1.1) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022364-12 | Sponsor Protocol Number: BAY86-5321/91745 | Start Date*: 2011-03-18 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema | |||||||||||||
Medical condition: Diabetic macular edema with central involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) ES (Completed) DK (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003816-19 | Sponsor Protocol Number: V4061 | Start Date*: 2016-10-14 |
Sponsor Name:ForSight VISION4, Inc | ||
Full Title: A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due toAge-Related Macular Degeneration | ||
Medical condition: Patients of either sex, 50 years of age or older, with a diagnosis of Choroidal Neovascularization CNV due to Age-Related Macular Degeneration AMD in the study eye | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: LV (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-005241-23 | Sponsor Protocol Number: 16.37 | Start Date*: 2017-04-19 | |||||||||||
Sponsor Name:Odense Universitetshospital | |||||||||||||
Full Title: Lonsurf - RII Lonsurf (TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer. A randomized phase II study | |||||||||||||
Medical condition: Metastatic, non-resectable and chemo-refractory colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005657-24 | Sponsor Protocol Number: PERMAD01 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Ulm | |||||||||||||
Full Title: Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter... | |||||||||||||
Medical condition: colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003329-40 | Sponsor Protocol Number: 15-API-01 | Start Date*: 2017-09-19 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melanoma | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002115-26 | Sponsor Protocol Number: FBH-001 | Start Date*: 2019-11-05 |
Sponsor Name:Institut Hospitalier Franco-Britanique | ||
Full Title: Cetuximab as salvage therapy in patients with neo wild-type RAS/RAF metastatic colorectal cancer. A Proof-of-concept study | ||
Medical condition: colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000674-28 | Sponsor Protocol Number: DMP-001 | Start Date*: 2019-07-31 | |||||||||||
Sponsor Name:Dipartimento di Medicina di Precisione - Università degli studi della Campania "L. Vanvitelli" | |||||||||||||
Full Title: A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC). | |||||||||||||
Medical condition: Patients with mCRC progressed after =2 lines of standard treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000095-42 | Sponsor Protocol Number: 1199.52 | Start Date*: 2014-10-08 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm.V | |||||||||||||
Full Title: A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therap... | |||||||||||||
Medical condition: Patients with metastatic colorectal cancer refractory to standards therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LU (Completed) IT (Completed) SE (Completed) AT (Completed) DK (Completed) BE (Completed) DE (Completed) PT (Completed) NL (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
